Background: A novel manufacturing industry is emerging to translate unique cellular therapy bioprocesses to robust, scaled manufacturing production for successful clinical translation.
Introduction
Regenerative medicine is an established and rapidly advancing research field targeted at the repair or replacement of damaged or diseased human cells, tissues or organs to restore normal function. 1, 2 The principle of cell culture application to tissue repair or replacement has been around since the late 1930s, with research accelerating in the 1990s during the emergence of the tissue engineering industry. 2 During the last 20 years this industry has evolved into the broader field of regenerative medicine, 2 due to significant expansion in the isolation, generation and application of therapeutically useful stem cells with the potential to provide revolutionary cell-based therapies for a wide range of degenerative and currently incurable disease states (e.g. cardiovascular conditions, diabetes, arthritis, cancer, haematopoietic-, neurological-, eye-and skin disorders). 3, 4 Of these, human embryonic stem cells (hESCs) are of significant importance as a potentially renewable source of cells for regenerative medicine applications due to their ability to selfrenew indefinitely and retain the potential to differentiate into every cell type. 5 -7 However, controversy and ethical concern surrounds hESC-derived therapies as their generation requires the destruction of human embryos. 7, 8 Yet, although it is only 13 years since hESCs were first isolated, 6 within the last few months Geron and Advanced Cell Technology received clearance in the USA to initiate clinical trials for hESC-derived therapies for treatment of thoracic spinal cord injury and two types of macular degeneration, respectively, 9 -11 thus illustrating the rapid progression within this field. Additionally, recent groundbreaking research into induced pluripotent stem (iPS) cells has provided a potential alternative source of pluripotent stem cells without the destruction of embryonic tissue. 7, 8 Although, currently, cell-based therapies using iPS cell technology are in their infancy, and concerns regarding efficiency of generation, in vivo differentiation and genetic stability have been described. 8 Regenerative medicine cell-based therapies or advanced therapy medicinal products 12 are assessed on an individual product basis for regulatory approval and classified according to the product technology, degree of manipulation and intended application. 12 -14 Exacting regulatory criteria means that most products are subject to clinical assessment for market approval, 14, 15 and as final regulatory guidelines are still being revised there are difficulties in traversing the regulatory framework. 16 However, there are some commercialized cell-based therapy products including an autologous chondrocyte therapy for cartilage repair, 17 and many more in clinical trials, for example autologous stem cell transplant cancer therapies, 4 and an allogeneic neural stem cell therapy for treatment of ischaemic stroke, whose first patient received treatment in November 2010. 18 Acceleration of pre-clinical therapies towards clinical trials is widely supported, for example over $220 million in collaborative funding from the California Institute of Regenerative Medicine was recently awarded to 14 projects for this purpose. 9 Regenerative medicine-processing applications typically involve using numerous biological input materials to manufacture a complex viable product that changes constantly in response to its environment, consequently the whole bioprocess is critical to the integrity of the product, unlike molecular therapies where the final product is distinct from cellculture bioprocessing. 19 The industry is therefore developing a unique bioprocessing model with novel manufacturing technologies and skills, whilst utilizing bioprocessing experience and solutions from other manufacturing industries where possible. 20 Technologies used in molecular therapeutics have served as a foundation for technology development for large-scale cellular therapeutics. 21 In parallel with progression towards clinical targets, a novel high-value regenerative medicine manufacturing industry is emerging, to translate laboratory bench-scale experimental processes into robust manufacturing processes for production at scale with consistent product quality, combined with production costs that will enable cell-based therapies realize their potential for patients for whom they are applicable. In 2007, the activity within the private sector of the regenerative medicine industry was approaching $2.5 billion. 2 Plans to address overarching issues, provide direction and advance the field of regenerative medicine and tissue engineering are in progress in many countries, for example the multi-agency tissue engineering science international working group (MATES IWG) strategic plan identifies activities and priorities to aid generation of clinical success by 2021. 22 This review breaks down the stem cell-based therapy bioprocess, highlighting key issues and areas timely for developing research to achieve this goal.
Bioprocessing challenges affecting cell-based therapies
Considering the whole bioprocess A classically defined process will identify all key process input variables (KPIV) and key process output variables (KPOV) with understanding of the range within which the critical input variables must be controlled to maintain final product specification. Process variation is extremely undesirable for manufacturing and good manufacturing practise (cGMP) processes, therefore a defined process will categorize process input variables into those that are statistically controlled, those that are not controlled yet there is scope for control and those that cannot be controlled and contribute to inherent statistical variation within the process. 23, 24 Fig. 1 illustrates the concept of a classically defined process in its simplest form. Developing this level of understanding on any complex manufacturing process is challenging, however for cell-based therapies the challenge is escalated. When considering the whole bioprocess, regulatory authorities regard all parts of the process as manufacturing steps, therefore each requires current cGMP compliance. 15 Depending on the complexity, bioprocessing time can range from weeks (frequently for autologous therapies) to months (e.g. hESC-derived differentiated cardiomyocytes).
6 Fig. 2 illustrates high level deconstruction of a generalized cell-based therapy bioprocess. Stem cell bioprocessing components and requirements (e.g. cell types, scaffolds, monitoring, modelling and characterization) were recently reviewed by Placzek et al. 25 When deconstructed and viewed as a whole, the bioprocess can be split into core cell processing activity, comprising a series of linked sub-processes and peripheral processes that may impact upon core processing if they are a source of variation. It is also important to consider that the bioprocess used to produce individual production units or therapeutic product lots fits within the overarching manufacturing facility process; typically comprising multiple production lines. Additionally lot size and scaling of lot size must be considered early to ensure the process and technologies used in clinical phase production enable scalable and commercially viable lot sizes for approved product release. 21 Defining KPIV is more than simply listing and defining all process inputs, which is a large task in itself on a complex biological process where many of those inputs comprise biologics that in themselves may be difficult to define to levels required. 7 Importantly, there is the added complexity of demonstrating that KPIV are critical for resultant product quality in a combinatorial process where inputs may act singly, agonistically or cumulatively on process outputs, and where the final process output is a viable human cell that currently cannot be comprehensively defined, thus determining cause and effect interactions and relationship to final product quality is immensely difficult. 16, 19 Application-dependent scalable bioprocessing Autologous and allogeneic cell-based therapy bioprocessing have key differences in terms of achievable scale, economic bioprocessing, cGMP burden, application of automation, potential for lot variation and risk of contamination and cross-contamination. Although autologous therapies have advantages in being patient tailored, without adverse immune response risk and economic during early development stage processing, they pose significant challenges downstream when more product lots are required, compared with allogeneic therapies where bioprocessing at scale can be potentially streamlined and more economic. 19 Autologous applications impact upon several stages of the generalized bioprocessing framework (Fig. 2) , including increased difficulty in achieving sufficient and consistent starting material without significant batch variation. If there is poor consistency between the cell number and cell quality from different patients, which range in age and severity of illness, it is more likely that there will be differences in the processing of the poorer input material (e.g. extended culture time, different passage or feeding stages, etc.) and of the final product. As allogeneic therapies are produced from a single source, it is more straightforward to place controls on the starting material entering the core activity. Yet allogeneic therapies require extensive safety testing to ensure there is no disease transmission risk, which accounts for .50% of the costs associated with allogeneic master cell banks. 21 Typically there is also a regulatory requirement for retention samples of starting material, 26 placing increased pressure on autologous cell harvest or extraction from starting material to obtain extra volume of the therapeutically important cells.
Frequently, autologous therapy bioprocessing is performed manually by skilled operators, which is generally more economic in early development and perhaps more applicable to the hospital environment, from which many therapies are derived. 19 The scale of autologous therapy bioprocessing increases by scale-out, yet as each patient product is considered a manufacturing lot this process requires increased levels of quality assurance and GMP review per product unit compared with scale-up of allogeneic bioprocessing where a single manufacturing lot can be used to treat many patients, 19 thus also distributing the costs associated with early safety testing. 21 However, achieving appropriate scale, in terms of required therapeutic cell numbers and current technology limitations for achievable cell densities at scale in an economic manner, is currently problematic for allogeneic therapies, for example, it is estimated that single doses of allogeneic hESC-derived beta cells for type 1 diabetes mellitus treatment or cardiomyocytes for cell replacement after cardiac infarction will be 10 8 and 10 9 , cells respectivley. 4, 7 Manual processes are not a viable option as microbial contamination is considered more probable in manual processes where operator interaction is required throughout core processing, particularly as the operator is a major source for dispersal of microbiological airborne contaminants. 19, 27 The risk of crosscontamination of an infectious agent from one patient lot infecting another patient lot, or the possibility of transfer to process reagents that may be used across patient lots, is of higher risk in autologous processes. Autologous bioprocesses must therefore either completely segregate individual patient products and all associated processing and reagents. Thereby escalating the challenges posed by process validation and cost and increasing process time by the requirement for dedicated equipment (e.g. incubator segregation) 28 and more frequent area cleaning to cGMP standards. Otherwise manufacturers may be able to perform simultaneous processing of several autologous products by demonstrating that the risk of cross-contamination is mitigated by using aseptic automation methods or sophisticated isolators with integral rapid vapour hydrogen peroxide sterilization. Cell-therapies derived from banked cell stocks may also have additional validation burden with regard to histocompatibility barriers 16 and demonstration of their purity, particularly as the estimated level of crosscontamination among commercially available cell banks is between 18 and 36%. 29 Stem cell-based therapies now dominate the regenerative medicine industry, and patient-specific primarily-autologous therapy medicine is an integral part of this. However, this shift is thought to be partially attributed towards an increase in allogeneic therapies, considered attractive from a simplified and more economically viable bioprocess and market scale perspective, 30 and it is important to note that many of the allogeneic therapies in current clinical trials use traditional flaskbased adherent cell culture processes. 21 
Common translational issues
Common drivers for process change when translating to scalable cGMP processing include reduction of contamination risks, meeting cGMP standards, reduction of cost of goods, increasing process robustness, reducing variation and increasing final product volumes. However, if little is known about process capability, whether the process is in sufficient statistical control, implementing these changes may negatively impact on process output and product quality, therefore the cost of product or batch failure and variation must be seriously considered. Processing costs invariably increase with scale and translation to GMP standards, as GMP grade material is required for both clinical trials and final production, 12 yet commonly some reagents used in pre-clinical studies are either unavailable at GMP grade because of commercial risks, or are considered too costly for these developmental studies, 16 where the cost of implementing change on the process downstream or the potential effect of later change on product quality or efficacy become secondary to near-term priorities. Additionally, the investment associated with clinical assessment and either running a GMP-processing facility or GMP-empowered clinic, or contracting the process to an external manufacturer are substantial.
bioprocessing at scale, this may be due to a lack of available specificity in requirements for generic bioprocessing products applicable to multiple therapies, but possibly more related to market risk and uncertainty of sustainable investment in products or enabling technologies that are currently only used by a select few in the emerging industry. Therefore, it is reasonable to suggest that during the estimated 10-15 years from development to market, 31 many cell-based therapy bioprocesses will encounter supply problems, thus highlighting the importance of sourcing alternative suppliers and manufacturers that feed into the core-processing activity (Fig. 2) . It is also important to mention that in addition to requiring redundancy in the supply chain feeding the bioprocess, that there must also be redundancy in the supply of the therapeutic product to ensure continuity, therefore a requirement for more than one production facility. Consideration of the impact of process changes with regard to process scale, supply chain and streamlining (i.e. to reduce cost of goods) should be re-iterated throughout product development from an early stage, as any process change during pre-market approval is likely to require validation or revalidation to demonstrate retention of product safety and efficacy, hence the design of the manufacturing process is critical. 19, 21 Considering general product safety, the major contamination risks common to both autologous and allogeneic therapies are process input contamination either from operators, core activity reagents or peripheral processes, and maintaining a controlled manufacturing environment is a significant contributor to cost. Many cell-based therapies are administered to patients without knowledge of the results of final product sterility tests due to the limited product shelf-life of these viable products and long incubation times of currently used classical microbiological test methods. 28 Although these current techniques for product safety assessment provide sufficient sensitivity to prevent adverse effects in the patient, 28 there is a requirement for improvement from the perspective of processing time and cost, for example by using Rapid Microbiological Methods or implementing the use of automation. 28 There is a common misconception that the use of foetal calf serum (FCS) in cGMP manufacture of cell-based therapies does not conform to current regulatory standards. However, the use of FCS from traceable animals in specific geographical locations according to manufacturing guidelines for products at risk of transmissible spongiform encephalopathies (TSE) is currently accepted by regulatory authorities. 32 However, there is movement away from FCS which is widely supported by regulatory authorities, industry and the scientific community to reduce medium costs and as risk mitigation against the potential of introducing TSE, or generating adverse immunogenic reactions, 33 as well as part of the widespread need to move towards more defined reagent components that reduce the risk of lot-to-lot variability. 9 In 2006, the first xeno-free hESC lines were established using mediumcontaining human serum and human feeder cells. 7 Due to increased risks of phenotypic alterations to the product, development of serumfree or xeno-free culture conditions must be considered early in the manufacturing stage plan. 21 It is also important to note that there are limitations on current knowledge of product safety, for example autologous T cells with gene modified T cell receptor (TCR) are undergoing clinical assessment in cancer patients, 34 yet it was very recently discovered that miss-pairing of introduced and exogenous TCR chains can lead to lethal graft versus host autoimmunity in murine models and only specific TCR modifications mitigate this risk, 34 thus therapies that currently do not have these modifications are likely to be severely delayed in overcoming these risks because of the need for vector re-design and validation. In order to generate safe sources of stem cells, the elimination of undesirable cells is critical, such as undifferentiated cells that pose in vivo teratoma or teratocarcinoma formation risks, 35 particularly as teratoma generation was demonstrated in vivo with a hESC-derived population of differentiated insulin-secreting b-cells containing ,0.2% of undifferentiated hESC biomarkers, and combined with the fact that for estimated required therapeutic doses 5, 35 the required purity level is as yet unattainable with current gold standard purification technologies, magnetic affinity cell sorting 35 and fluorescence activated cell sorting. 28 Other critical bioprocessing bottlenecks are washing and volume reduction of harvested product, where molecular therapeutics technologies such as continuous centrifugation and tangenital flow filtration are being developed with specific attention to retention of cell-based therapy product quality. 21 It will always be problematic to validate cell-based therapy functional assays to the standard of pharmaceutical assays due to the intrinsic variation of a human cell population, rarity of gold standard reference analytes, limitation by current knowledge of specific cell processes and lack of appropriate measures of product quality, which are usually based on surrogate biomarker measurements (e.g. mean population expression of gene or protein of interest) that phenotypically distinguish cell populations and can be used as indicators of product efficacy or function but direct correlation with efficacy or function is generally intangible. 16 Cell-specific assays that provide direct indication of desired in vivo function or efficacy are rare. One example is the analysis of spontaneous beating of embryoid bodies in hESC-derived cardiomyocyte bioprocessing. 36 It is therefore extremely difficult to pinpoint standards for bioprocessing assays and the degree of validation required such that they can be used for in-process monitoring or product-release testing. Currently, there are no international standards documents published to guide testing and bioprocessing of cell-based therapies, 31 and with specific regard to assay validation the general approach is evidence based (utilizing historical pre-clinical and early clinical data) to enable the manufacturer to rationally argue that the validation performed is considered acceptable.
One of the most commonly used methods of in-process measurement within core processing is cell number and cell viability determination, and maintaining viable, robust and reproducible cell cultures is directly influenced by the accuracy with which these measurements are determined, because differences in cell proliferation rates can be diagnostic of cell state, and because many controlled culture processes or assays require specific cell density maintenance. 6 Adherent cell dissociation is inherently linked to measuring cell number and viability as most methods anticipated to be suitable for scalable bioprocessing require single-cell suspensions, 6 and for some cell and culture types, such as hESC colony cultures, single-cell suspension dissociation processes can have detrimental effects on downstream culture. 6, 9 Many current tests for viability are invasive and open to interpretation, for example membrane integrity methods are easily confounded by cells without membrane integrity that are capable of recovery and do not give information on proliferating cells, 37 and measures of metabolic activity 38 can fluctuate independent of viability. Cryopreservation is another process used generically in cell-therapy bioprocessing, sometimes at multiple stages within the whole bioprocess; for storage of input cells as well as final product. Cryopreservation is used to significantly extend product shelf-life and aid product distribution. However, widespread issues have been observed with cryopreservation including cell loss, reduced viability and reduced expansion rates of recovered cells, particularly as latent effects of cryopreservation are often undetected until later, for example delayed onset cell death may occur 24 -48 h post-thawing. 39 Efforts to address these issues are a growing area of research driven by increasing understanding of supply chain issues affecting therapeutic product supply. However, a generic solution is far from straightforward as there is a lack of standardization of cryopreservation protocols, and there must be separation of potential variation within the cryopreservation process and potential variation within the thawing process, the latter likely occurring in the clinical environment.
Bioprocessing improvement tools

Automation and enabling technologies
Automation is widely considered important for overcoming translational bioprocessing issues as it can be used as a tool to improve process capability, remove operator-dependent variation, understand process variation by allowing the automation of complex experimental protocols, and enable scalable culture with controlled cost. 25,37,40 -42 Automation is widely employed in large-scale Chinese hamster ovary (CHO) cell culture for pharmaceutical applications, 6 yet existing industry scaling technologies are not readily adapted to culture of adherent cells which are common to cell-based therapies, and automation emulating manual adherent bioprocessing techniques is considered important to progress these products to commercial reality. 40 Although manual bioprocessing may be more economically feasible for smaller scale bioprocesses 17 and during product development, it is considered high risk due to the individualized nature of intricate processing techniques by specialist cell culture technicians; the difficulties in transferring manual bioprocesses to alternative sites (e.g. contract manufacturing); and the increased potential for contamination, processing inconsistency and product variation. 19, 25 These risks will become more critical to the viability of the process as specifications of products will become tighter as they move up the regulatory pathway. Initial capital outlay for scaleable automation may be high, but the potential improvements in process consistency, control, product quality, failure risks and reduced labour are important for scaled economic viability of the final manufacturing bioprocess for large-scale clinical assessment and commercialization. Disposable closed culture systems that do not require specialist operators are considered attractive for patient-specific cell-therapy bioprocessing and such systems have been used for clinical scale haematopoietic stem cell and T-cell expansion. 16 Table 1 summarizes the advantages and disadvantages of methodologies for cell-based therapy bioprocessing that are semi-or fully automatable.
Transferring cell culture bioprocesses from manual to automated procedures can be difficult, for example semi-automated culture of adherent hESCs in 6-well plates was attempted with a system capable of performing automated media change, supplement addition and cell harvest for over 150 plates, with manual interaction required for cell dissociation and centrifugation, 41 the latter process being particularly difficult to automate whilst retaining asepsis. However, the system was unsuitable for cell-based therapy bioprocessing due to the considerable risk for well-to-well cross-contamination, and being unlikely to achieve required therapeutic scale. 6, 7 Last year, several reports demonstrated that hESCs can be cultured in suspension without microcarrier attachment, 9 thereby possibly suggesting the potential to move away from the difficulties associated with adherent hESC culture towards more readily controllable suspension bioreactors.
Many suspension bioreactor systems are semi-automated, having on-line monitoring and culture maintenance capabilities, but are rarely designed as components of fully automated bioprocessing systems or as complete scaleable units considering product supply, quality and packaging. Potential extension of expansion capability for increasing cell densities and scale-out of bioreactors is possible by applying robotic processing, 43 and real-time online monitoring when combined with improved process control equipment and techniques have the ability to enable robust and reproducible bioprocesses for cell-based therapies. 37 A concept being built in to new development technologies such as the advanced microscale bioreactor (Ambr) system (The Automation Partnership, available at http://www.automationpartnership.com), which is a high through-put automated platform comprising up to 48 miniature suspension bioreactors with controlled temperature, pH, dissolved oxygen and carbon dioxide tension and stirring. This automated platform which is designed to mimic larger scale industrially relevant suspension bioreactors was primarily developed for CHO culture, and highlights a developing area of cost-effective scaled-down automated systems for use in research and pre-clinical development to aid bioprocess translation and adoption of automation.
There are a range of monitoring techniques for cell bioprocess that can be applied to automated systems, reviewed previously by Lim et al. 37 and Placzek et al., however few have been applied to stem cell cultures to the level they can be used for cGMP manufacturing purposes, and parallel monitoring of multiple process variables is limited to only certain parameters. Automation of in-process monitoring techniques, either as part of a fully automated platform, or as generic automated modules for sub-processes are useful for reducing the often subjective and time-consuming nature and potential variation of current in-process measurements, which compromise accuracy. The counting error of the trypan blue dye exclusion membrane integrity method for cell number and viability measurements reduced from 20% associated with a manual haemocytometer to 5% with automation. 44 Improvements in measurement capability are required, as well as application of modular automation to other generic sub-processes, and the use of quantitative non-invasive and non-destructive automated imaging techniques (e.g. Cell-IQ w from Chipman Technologies available at http://www.chipmantech.com) are expected to become more prevalent for on-line monitoring.
Some commercialized products are being produced using productspecific semi-automated procedures and vessels, 19 but broad application robotic systems capable of processing different vessel types are likely to be more useful from the perspective of supply chain interruptions. Although closed processing, for example via medium perfusion is advantageous for aseptic processing, vessels typically used for open processes (e.g. culture flasks) were successfully transferred to automation by performing all manipulations in a closed robotic handling processing unit that maintains laminar airflow using well-established biological safety cabinet technology. 45 Originally developed for industrial production of erythropoietin, 45 this type of processing has since been applied to allogeneic and autologous cell processing (CompacT Cellbase, The Automation Partnership). In fact the Healthcare engineering group at Loughborough University was the first to automate the expansion of primary human bone marrow-derived mesenchymal stem cells (hMSCs) using this fully automated cell culture platform, 46 and have since performed several novel demonstrators of the transfer of manual human cell culture bioprocesses to automation, including hESCs, 47 and a representative 'product' formulation expansion for a clinically relevant allogeneic neural stem cell line to GMP release specifications, 42 thus demonstrating transfer of (in some cases centrifugedependent processes) to a generic industrially relevant, commercially available platform (and centrifuge-independent processing). More recently, the Healthcare Engineering group performed a process capability analysis comparing manual and automated in vitro expansion of adherent human cells using this automated platform. The analysis demonstrated that the manual process had poor capability due to excess variability in comparison to the automated process, and that, by centreing the process mean of the desired output specification, a 7-fold improvement in process performance could be achieved. 48 The authors also contributed to the development of a next generation GMP-validatable version of the platform through sophisticated re-design and rigorous testing with regard to viable particle monitoring and detection of droplets and micro-splashes during liquid handling using a viable particle equivalent (Glogerm TM , available at http://www. glogerm.com) for traceability in cross-contamination validation assays (unpublished author data).
From the perspectives of achieving regulatory approval and costeffective manufacture, there is a requirement for cell-based therapy bioprocessing to become more streamlined and standardized; this will enable the development and adoption of more automated modular equipment for generic parts of the process and automated processing systems capable of processing multiple therapies.
Process improvement tools
Due to different micro-environments in the bioprocess and cell sensitivity to extrinsic factors, cell products always incorporate some heterogeneity. However, uncharacterized and uncontrolled bioprocesses are extremely undesirable, potentially leading to low product quality and purity. 37 Many cell-based therapy bioprocesses are considered high risk with significant end-point testing and failure rates due to poor control of unknown attributes critical to quality. Conventional 'one factor at a time' experimental approaches for process experimentation assume a lack of statistical interaction of process inputs on process responses, whereas cell-culture bioprocess inputs are highly likely to be interdependent, thus confounding the analysis of such studies. 23, 24 Typical drivers for process improvement are related to specifications that significantly impact upon the commercial viability of a process, or are critical for final product quality (e.g. proliferation rate, pluripotency, product viability, cost, failure rate). Six sigma 49 inspired quality engineering tools can be used for systematic data driven decisionmaking to improve a process or parts of the process. Application of these tools follows a systematic approach of measuring the baseline process of interest to assess whether the desired process outputs and their level of variation are within specification and to assess whether the process is statistically controlled (e.g. by use of control charts). Processes that are statistically uncontrolled, or have very high intrinsic variation, are respectively impossible, or very expensive, to characterize with statistical resolution. In addition to these baseline measurements, the process can be deconstructed using tiered process mapping from high-level process overview (Fig. 2) to lower sub-process levels with increasing sub-process detail. Breaking the process down in this manner enables the identification of potential KPIV and KPOV (Fig. 1) at the required level and potential critical control points within the process. 24 The complexity of cell culture bioprocesses makes them hard to define 37 and the advantages of this technique is that resource can be focused on characterizing, optimizing and improving critical subprocess control points to generate a more controlled complete process. 24 In order to achieve data-driven assessment statistical design of experiments (DOE) can be used to identify process input factors and interactions affecting process responses or outputs, thereby facilitating process characterization. 16, 25, 37 Finally, any changes to the process must be validated with reference to baseline measurements.
DOE is typically employed for the analysis of principle and interactive effects of a process objective, for example by screening experiments, response surface modelling or regression modelling, using the Bioprocessing of cell-based therapies British Medical Bulletin 2011;100 minimum effort necessary to generate the maximum amount of information. 16, 25, 37 The methodology was originally described in the early 20th century 50 and is a commonplace tool among other complex manufacturing industries. 51, 24 Although not extensive, adoption of DOE for in vitro cell culture and cell-based therapy bioprocessing is increasing, particularly for culture parameter screening and process characterization purposes, 16,52 -54 and was recently used in combination with a scalable automated platform for factorial screening of significant culture parameter interactions and magnitude of their effect on process responses for expansion of primary bone marrow-derived hMSCs. 23 DOE can also be used to identify tolerance within a process, in terms of understanding the latitude in which KPIV can move without sending the process out of specification, to further characterize and define the operating space of the process 24 and implement critical process controls and reduce the risk of process failure by providing a safety margin of acceptable variation at that critical control point.
Improving the understanding and control of a bioprocess is essential in ensuring process reproducibility and product quality. 16, 25, 37 However, it is important to note that the value of a systematic process engineering and optimization approach is dependent on the relevance of the selected process responses, and herein lies the difficulty, as any sub-process outputs or responses used for this purpose must be linked to the control of critical input to the next sub-process and be predictive of final critical to quality product attributes, for example high levels of variation of cell viability at any stage will certainly impact downstream cell quality. Yet as alluded to previously, relationships between other commonly used methods of cell characterization and final product quality are less understood, 16 but this is an area of growing research, for example Lim et al. have previously reviewed the application of process control strategies including DOE, as well as process monitoring and analytical tools for time-and cost-effective haematopoietic stem cell expansion and differentiation for clinical use. 37 
Summary
A range of bioprocessing challenges for scaled manufacture of regenerative medicine cell-based therapies remain in this rapidly advancing field, as well as wider translational barriers that significantly impact upon bioprocessing issues. These include a need for increased regulatory certainty as the regulatory framework continues to evolve, enabling cost-effectiveness on multiple levels (cost of goods, manufacturing technologies, reimbursement policies), improving product characterization and performance specification and ensuring early clinical end-user collaboration to establish clinical utility, cost-effectiveness and enable timely post-approval clinical adoption, the resultant impact upon early translational bioprocessing being that there are limits on current understanding of how to fulfil all requirements. However, for the more localized bioprocessing challenges, more extensive use and adaptation of some of the process improvement tools that are commonplace among other complex manufacturing industries and a consideration of the whole bioprocess concept from early product and process development will aid clinical translation of these revolutionary therapies. Due to lead time on products achieving commercialization, many developers are likely to have more advanced next generation products in the preclinical domain than those being approved, it is therefore important to streamline and standardize cell-based therapy bioprocessing and manufacture where possible in order to move away from highly individualized manufacturing strategies for each product in development. The processes should fit within an overall manufacturing production system, and where current automation is capable of replicating manual processes, if we consider future production systems there must be a move towards machine tools that are more advanced than a human manual process. To achieve this manufacturing goal there must be knowledge of the level of variation achieved in current processes, and the variation the product is allowed by the regulator and its application, to generate understanding of where improvements need to be made in order to be able to design bioprocesses and next generation production systems.
